인쇄하기
취소

Erbitux renews RSA for the first time

Published: 2018-05-16 16:04:50
Updated: 2018-05-16 16:04:50

Erbitux, a metastatic rectal and colon cancer therapy, successfully renewed the RSA agreement. This is the first case which renewed the agreement through a renegotiation.

According to the National Health Insurance Service(NHIS) on the 14th, Merck and the NHIS have concluded the RSA revaluation agreement this early month.

The term of the renewal is 4 years.

Erbitux 5mg/ml(cetuximab), a Merck’...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.